Standard BioTools Inc. (NASDAQ:LAB) Major Shareholder Caligan Partners Lp Acquires 46,009 Shares

Standard BioTools Inc. (NASDAQ:LAB – Get Rating) major shareholder Caligan Partners Lp acquired 46,009 shares of Standard BioTools stock in a transaction on Wednesday, August 3rd. The shares were bought at an average cost of $1.74 per share, with a total value of $80,055.66. Following the completion of the transaction, the insider now owns 11,189,663 shares of the company’s stock, valued at $19,470,013.62. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Caligan Partners Lp also recently made the following trade(s):

• On Monday, August 1st, Caligan Partners Lp bought 210,200 shares of Standard BioTools stock. The shares were bought at an average cost of $1.48 per share, with a total value of $311,096.00.
• On Friday, July 29th, Caligan Partners Lp purchased 137,648 shares of Standard BioTools stock. The stock was bought at an average cost of $1.42 per share, for a total transaction of $195,460.16.
• On Monday, June 13th, Caligan Partners Lp acquired 100,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.70 per share, with a total value of $170,000.00.
• On Thursday, June 2nd, Caligan Partners Lp acquired 200,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.92 per share, for a total transaction of $384,000.00.

Standard BioTools Price Performance

Shares of Standard BioTools stock opened at $1.89 on Friday. The company has a debt-to-equity ratio of 4.52, a current ratio of 1.55 and a quick ratio of 1.06. The company has a 50-day simple moving average of $1.71. Standard BioTools Inc. has a 52-week low of $1.28 and a 52-week high of $7.31.

Standard BioTools (NASDAQ:LAB – Get Rating) last announced its earnings results on Thursday, May 5th. The company reported ($0.31) earnings per share (EPS) for the quarter. Standard BioTools had a negative return on equity of 63.43% and a negative net margin of 93.89%. The business had revenue of $26.50 million for the quarter.

Standard BioTools Company Profile

(Get Rating)

Standard BioTools Inc creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.